Orchestra BioMed Holdings, Inc. (OBIO)
OBIO Stock Price Chart
Explore Orchestra BioMed Holdings, Inc. interactive price chart. Choose custom timeframes to analyze OBIO price movements and trends.
OBIO Company Profile
Discover essential business fundamentals and corporate details for Orchestra BioMed Holdings, Inc. (OBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Aug 2020
Employees
70.00
Website
https://orchestrabiomed.comCEO
David P. Hochman
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
OBIO Financial Timeline
Browse a chronological timeline of Orchestra BioMed Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.48.
Earnings released on 12 Aug 2025
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%, while revenue for the quarter reached $836.00K , beating expectations by +7.34%.
Earnings released on 2 Apr 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $253.00K , missing expectations by -51.56%.
Earnings released on 26 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.43 by +13.95%, while revenue for the quarter reached $253.00K .
Earnings released on 12 Nov 2024
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $987.00K , beating expectations by +40.35%.
Earnings released on 12 Aug 2024
EPS came in at -$0.45 falling short of the estimated -$0.41 by -9.76%, while revenue for the quarter reached $778.00K , missing expectations by -8.47%.
Earnings released on 13 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.40 by +5.00%, while revenue for the quarter reached $620.00K , missing expectations by -34.74%.
Earnings released on 27 Mar 2024
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%, while revenue for the quarter reached $262.00K , missing expectations by -73.66%.
Earnings released on 13 Nov 2023
EPS came in at -$0.38 surpassing the estimated -$0.39 by +2.56%, while revenue for the quarter reached $419.00K , missing expectations by -53.18%.
Earnings released on 10 Aug 2023
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%, while revenue for the quarter reached $915.00K , beating expectations by +29.60%.
Earnings released on 12 May 2023
EPS came in at -$0.40 falling short of the estimated -$0.28 by -42.86%, while revenue for the quarter reached $1.16M , beating expectations by +71.18%.
Earnings released on 25 Jan 2023
EPS came in at -$0.08 surpassing the estimated -$0.43 by +81.82%, while revenue for the quarter reached $1.10M , beating expectations by +55.35%.
Earnings released on 16 Dec 2022
EPS came in at -$0.05 , while revenue for the quarter reached $1.16M .
Earnings released on 30 Jun 2022
EPS came in at -$0.25 , while revenue for the quarter reached $401.00K .
Earnings released on 31 Mar 2022
EPS came in at -$0.18 , while revenue for the quarter reached $866.00K .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached -$2.45M .
Earnings released on 30 Sept 2021
EPS came in at -$0.00 , while revenue for the quarter reached $1.33M .
Earnings released on 30 Jun 2021
EPS came in at -$0.00 , while revenue for the quarter reached -$978.00K .
Earnings released on 31 Mar 2021
EPS came in at -$0.01 , while revenue for the quarter reached $1.32M .
OBIO Stock Performance
Access detailed OBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.